Recombinant Anti-CD37 x Anti-CD64 Bispecific Antibody (scFv-IgG) is formed by an IgG and two scFv fragments. The scFvs from an anti-CD37 antibody variable domain are respectively connected to the N terminus of the anti-CD64 IgG heavy chains or light chains to form scFv-(H)IgG or scFv-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Non-Hodgkin's lymphoma (NHL); Diffuse large B cell lymphoma (DLBCL); Chronic lymphocytic leukemia (CLL) therapy.